Trial · NCT00978731
Results by group92
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 92
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. | Chronic Myelogenous Leukemia (CML): QD Dosing at Study Entry | Deaths | 3 | participants | |
| Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. | CML: BID Dosing at Study Entry | Deaths | 2 | participants | |
| Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. | Accelerated Phase CML: BID Dosing at Study Entry | Deaths | 1 | participants | |
| Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. | Myeloid Blast Phase CML: BID Dosing at Study Entry | Deaths | 1 | participants | |
| Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. | Chronic Myelogenous Leukemia (CML): QD Dosing at Study Entry | SAEs | 10 | participants | |
| Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. | CML: BID Dosing at Study Entry | SAEs | 9 | participants | |
| Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. | Accelerated Phase CML: BID Dosing at Study Entry | SAEs | 3 | participants | |
| Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. | Myeloid Blast Phase CML: BID Dosing at Study Entry | SAEs | 3 | participants | |
| Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. | Chronic Myelogenous Leukemia (CML): QD Dosing at Study Entry | AEs | 22 | participants | |
| Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. | CML: BID Dosing at Study Entry | AEs | 15 | participants | |
| Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. | Accelerated Phase CML: BID Dosing at Study Entry | AEs | 5 | participants | |
| Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. | Myeloid Blast Phase CML: BID Dosing at Study Entry | AEs | 4 | participants | |
| Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. | Chronic Myelogenous Leukemia (CML): QD Dosing at Study Entry | Discontinuation due to AEs | 4 | participants | |
| Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. | CML: BID Dosing at Study Entry | Discontinuation due to AEs | 3 | participants | |
| Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. | Accelerated Phase CML: BID Dosing at Study Entry | Discontinuation due to AEs | 1 | participants | |
| Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. | Myeloid Blast Phase CML: BID Dosing at Study Entry | Discontinuation due to AEs | 0 | participants | |
| Number of Participants Who Experienced Drug-related AEs and Drug-related SAEs. | Chronic Myelogenous Leukemia (CML): QD Dosing at Study Entry | Drug-related AEs | 14 | participants | |
| Number of Participants Who Experienced Drug-related AEs and Drug-related SAEs. | CML: BID Dosing at Study Entry | Drug-related AEs | 9 | participants | |
| Number of Participants Who Experienced Drug-related AEs and Drug-related SAEs. | Accelerated Phase CML: BID Dosing at Study Entry | Drug-related AEs | 3 | participants | |
| Number of Participants Who Experienced Drug-related AEs and Drug-related SAEs. | Myeloid Blast Phase CML: BID Dosing at Study Entry | Drug-related AEs | 3 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00978731/results